Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004

INOTIV, INC.

(NOTV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings

05/11/2021 | 04:06pm EDT

WEST LAFAYETTE, Ind., May 11, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that Kenneth Swart, Ph.D., has joined the Company as Vice President, Bioanalytical Sciences. Dr. Swart’s arrival follows the closing of business acquisitions which expand the Company’s pharmacology, immunohistochemistry and histopathology businesses, as well as the announcement of planned investments in laboratory sciences and solutions focused on assisting clients discover and develop novel therapies.

“At a time when our clients’ assets reflect a blend of traditional oral drug candidates to gene therapies and vaccines, the infusion of Dr. Swart’s experience and leadership into our regulated bioanalytical, DMPK and cell & molecular biology team effort aligns with recent internal investments in our contract research solutions,” said Dr. Michael Baim, Senior Vice President of Bioanalytical Operations. Dr. Baim continued, “We believe that Dr. Swart’s extensive experience in bioanalysis, biomarker discovery and development, as well as translational pharmacology and genomic medicine, is a perfect match to the portion of our client base immersed in treatment discoveries for chronic inflammation, neurological disease, oncology & hematology, infectious disease, immunology, and rare & neglected disease.”

Dr. Swart joins Inotiv with more than three decades of global experience supporting all aspects of clinical development, including a recent tenure at Parexel, where he led and influenced a 20-year evolution in bioanalytical sciences and translational pharmacology, as well as a developing genomic and individualized medicines arena. As a result of his bioanalytical, pharmacology and immunology contributions to the field, Dr. Swart has maintained a rich tenure in the Departments of Bioanalytical and Organic Chemistry at the University of the Free State (Bloemfontein, South Africa).

“I am pleased to be part of a company with multidisciplinary expertise and a dedication to delivering solutions for clients pursuing small molecule and biotherapeutic discovery,” said Dr. Swart. “I look forward to assisting the team in expanding these service offerings in a GLP facility.”

Dr. Swart holds a Ph.D. in Pharmacology and Bioanalytical Chemistry, a Master of Medical Science in Pharmacology, a Bachelor of Medical Science (Hons) in Pharmacology, and a Bachelor of Science in Chemistry and Physiology, all from the University of the Free State in South Africa. He is a member of the American Society of Mass Spectrometry and served as board member and scientific editor for the Journal of Chromatographia.

About the Company

Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact Investor Relations
Inotiv, Inc. The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer Kalle Ahl, CFA
(765) 497-8381 (212) 836-9614
btaylor@inotivco.com kahl@equityny.com
   
  Devin Sullivan
  (212) 836-9608
  dsullivan@equityny.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf789680-de46-464b-9780-eb76715f79dd


Primary Logo

Kenneth Swart, Ph.D.

Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings

ę GlobeNewswire 2021
All news about INOTIV, INC.
08/02SECTOR UPDATE : Health Care Stocks Add Support As Monday Trading Turns Increasin..
MT
08/02INOTIV : Acquires Gateway Pharmacology Labs, Adding to Its Drug Metabolism, Phar..
MT
08/02INOTIV : Announces Acquisition of Gateway Pharmacology Laboratories
AQ
08/02Inotiv, Inc. acquired Gateway Pharmacology Laboratories LLC.
CI
07/30FRONTAGE : Concludes Purchase of US-Based Quintara Discovery
MT
07/22INOTIV : to Report Third Quarter Fiscal 2021 Financial Results and Host Conferen..
AQ
07/21Certain Common Shares of Inotiv, Inc. are subject to a Lock-Up Agreement Endi..
CI
07/21Certain Options of Inotiv, Inc. are subject to a Lock-Up Agreement Ending on ..
CI
07/15SECTOR UPDATE : Health Care Stocks Lower Just Ahead of Closing Bell
MT
07/15SECTOR UPDATE : Health Care Stocks Lacking Much Traction
MT
More news
Financials (USD)
Sales 2021 80,2 M - -
Net income 2021 -2,26 M - -
Net Debt 2021 - - -
P/E ratio 2021 -145x
Yield 2021 -
Capitalization 413 M 413 M -
Capi. / Sales 2021 5,15x
Capi. / Sales 2022 3,27x
Nbr of Employees 409
Free-Float 62,3%
Chart INOTIV, INC.
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 26,09 $
Average target price 36,00 $
Spread / Average Target 38,0%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.0.00%413
MODERNA, INC.231.78%139 174
LONZA GROUP AG25.60%58 688
IQVIA HOLDINGS INC.38.03%47 386
CELLTRION, INC.-26.60%31 285
SEAGEN INC.-11.93%28 062